Outcome of Adenoid Cystic Carcinoma of Head and Neck After Postoperative Intensity Modulation Radiotherapy: A Single Institution Study

Peng Xu1
Shuo Wang1
Yukun Luo1
Jun Yin1
Yazid Belkacemi2
Shun Lu1
Mei Feng1
Jinyi Lang1

1Department of Radiation Oncology, Sichuan Cancer Hospital and Research Institute, Chengdu, People’s Republic of China; 2Department of Radiation Oncology, APHP – University Hospital of Henri Mondor, Creteil, France

Objective: This study was retrospectively evaluated the outcome of postoperative intensity modulation radiotherapy (IMRT) for patients with adenoid cystic carcinoma of head and neck (ACCHN), and identified the unfavorable prognostic factors.

Methods: Fifty-five ACCHN patients treated in Sichuan Cancer Hospital between January 2007 and December 2016 were retrospectively evaluated. Median age of patient was 47 years (range, 21–73 years). Thirty-five patients were male and 20 were female. In 30 patients, tumors were located in major salivary glands (54.5%), and 25 patients in minor salivary glands (45.5%). The numbers of R0, R1, and R2 surgical resection classification patients were 22 (40.0%), 20 (36.4%), and 13 (23.6%). The median total RT dose was 62 Gy (range, 46–72 Gy), and 54.5% of patients were treated with adjuvant chemotherapy. Statistical analyses were performed using the Log rank test for univariate analysis and the Cox proportional hazard model for multivariate analysis.

Results: Median follow-up period was 68.5 months (12–132 months). The 5-year local-regional recurrence-free survival (LRRFS), distant metastasis-free survival (DMFS) and overall survival (OS) were 93.9%, 75.3% and 82.5%. In univariate analysis, T stages (p=0.025) and AJCC stages (p=0.036) were the prognostic factors for OS; Age (p=0.042), T stages (p=0.025), N stages (p=0.021), AJCC stages (p=0.021) and adjuvant chemotherapy (p=0.010) were the prognostic factors for DMFS; T stage (p=0.049) was the prognostic factor for LRRFS. In multivariate factors analyses, T stages (p=0.026), AJCC stages (p=0.028) and RT dose (p=0.025) were the significant prognosticators for OS. The most common acute toxicities over three degrees were myelosuppression (5.5%), mucositis (9.1%) and dermatitis (1.8%).

Conclusion: Postoperative IMRT seems to achieve reasonable local-regional control and OS in patients with adenoid cystic carcinoma of head and neck, with acceptable treatment relative toxicities.

Keywords: ACCHN, postoperative radiotherapy, IMRT, clinical efficacy, prognostic analysis

Introduction

Adenoid cystic carcinoma (ACC) is an uncommon tumor of the head and neck, accounting for about 1% of head and neck malignancies and 10% of malignant tumors of the salivary glands. The most common location of ACC often occurs in large salivary glands (parotid glands, submandibular glands, sublingual glands) and...
small salivary glands (palate, nasal cavity, sinuses, tongue, tear glands, trachea, etc).\(^1\) In addition, head and neck adenoid cystic carcinoma (ACCHN) is often has a high recurrence rate and occurs as advanced tendency for distant metastasis, often in the form of lung, liver, and bone.\(^\text{2,3}\) ACCHN occurred in all age groups, with higher incidence in middle-aged and older patients, women slightly more likely than men.\(^4\) The standard treatment method is surgical excision, and then according to the surgical margin and histopathological results, postoperative adjuvant radiotherapy is recommended.\(^1\) However, due to the neural invasion characteristic of ACCHN, it is difficult to obtain negative surgical margins even if complete resection can be evaluated by preoperative imaging.

Because of the low incidence of ACCHN, survival has been rarely reported. Most postoperative radiotherapy is conformal radiotherapy.\(^5,6\) This study reported the outcome and toxicity for ACCHN patients treated by surgery combined with intensity modulated conformal radiotherapy (IMRT) in a single institute.

**Materials and Methods**

**Ethics Statement**
All procedures performed involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the ethical committees of Sichuan Cancer Hospital & Institute, Chengdu, China. All patients provided informed consent.

All investigated patients presented between from January 2007 to December 2016, with pathologically confirmed ACC and no distant metastasis. Among them, five patients were lost to follow-up, two cases have not completed the postoperative radiotherapy, and 10 cases were treated by conformal radiotherapy, a total of 55 patients were included in the retrospective analysis. The clinical characteristics and treatments of patients are shown in Table 1.

All the patients underwent surgery and postoperative adjuvant IMRT. Postoperative pathological analysis showed that the total resection was R0, the microscopic residual was R1 and the macroscopic residual was R2. Postoperative residual area (GTV) and neck lymph node metastasis (GTV-N) were sketched according to the residual area and positive metastatic lymph node shown by CT, MRI or PET/CT. CTV1 was the postoperative tumor bed area, and CTV2 was the lymph drainage area. Prescription doses for each planned target area were GTV/GTV-N 65.0–73.0Gy (median 66Gy). Patients with R0&R1 margins were treated with CTV1 50–66Gy (median 54Gy) and CTV2 46–55Gy (median 48Gy). Twenty-nine (54.5%) patients received postoperative adjuvant chemotherapy; chemotherapy drugs were based on cisplatin, and the median cycle of chemotherapy was three.

Acute reactions and late complications were evaluated according to the Common Terminology Criteria for Adverse Events version 4.0.\(^7\) The patients were followed up every three months for one year after radiotherapy, every six months for 2–3 years, and annually after three years. Regular follow-up studies included physical examination, blood tests, chest X-ray/CT, abdominal ultrasound, head and neck MRI.

**Table 1 Patient Characteristics**

| Characteristics                  | Total Patients (%) |
|----------------------------------|--------------------|
| Gender                           |                    |
| Male                             | 35 (63.6)          |
| Female                           | 20 (36.4)          |
| Age, years                       |                    |
| ≤47                              | 28 (50.9)          |
| >47                              | 27 (49.1)          |
| Primary site                     |                    |
| Large salivary gland             | 30 (54.5)          |
| Small salivary gland             | 25 (45.5)          |
| T stages                         |                    |
| T1–2                             | 24 (43.6)          |
| T3–4                             | 31 (56.4)          |
| N stages                         |                    |
| N0                               | 51 (92.7)          |
| N1–2                             | 4 (7.3)            |
| AJCC stages                      |                    |
| I–II                             | 23 (41.8)          |
| III–IVB                          | 32 (58.2)          |
| Surgical resection level         |                    |
| R0                               | 22 (40.0)          |
| R1                               | 20 (36.4)          |
| R2                               | 13 (23.6)          |
| Chemotherapy                     |                    |
| No                               | 26 (47.3)          |
| Yes                              | 29 (52.7)          |
| Radiotherapy dose                |                    |
| <60Gy                            | 18 (32.7)          |
| ≥60Gy                            | 37 (67.3)          |
performed with the Cox proportional-hazards model. All p values are two-sided and p values of less than 0.05 were considered to be statistically significant.

**Results**

Median age of the patients was 47 years (range, 21–74 years), of whom 35 were male and 20 females (1.75:1). AJCC stage (7th edition) I, II, III, IV patients were 3 (5.5%), 20 (36.4%), 12 (21.8%) and 20 cases (36.4%), respectively. In 15 cases (27.3%) tumor arose in the parotid glands, 7 cases (12.7%) in the submandibular glands and 8 cases (14.5%) in sublingual glands. Pathological margins were R0 in 22 (40.0%) patients, R1 in 20 (36.4%) patients and R2 in 13 (23.6%) patients. Median follow-up time for the whole group was 68.5 months (range, 12–132 months). Local regional recurrence (LRR) occurred in four cases (7.3%), distant metastasis (DM) occurred in 14 cases (25.5%), and nine (16.4%) patients death. Main sites of distant metastasis were the lungs (78.6%), bones (28.6%), liver (21.4%), and brain (7.1%). Median survival time for the whole group was 58.6 months. The 5-year LRRFS, DMFS and OS were 93.9%, 75.3% and 82.5%, respectively (Figure 1). Table 2 lists the results of Log rank tests for the candidate prognostic factors. In the univariate analysis, the following parameters were associated with overall survival rate: T stages (p=0.025), and AJCC stages (p=0.036). Additionally, T stages is also significant associated with DMFS (p=0.049). However, gender, surgical resection level, postoperative radiotherapy dose and other factors did not show significant association with clinical outcome. The significant effects of T stages (T1/2 and T3/4) on the OS, LRRFS and DFMS are seen in Figure 2.

In multivariate analysis, T stages (p=0.026) and AJCC stages (p=0.028) remained statistically significant association with OS after adjustment (Table 3). Factors of independent importance on the DFMS were N stages (p=0.017) and AJCC stages (p=0.040).

As shown in Table 4, acute adverse reactions of grade 3 or above mainly included myelosuppression (3 cases, 5.5%), mucositis (5 cases, 9.1%), and dermatitis (1 case, 1.8%). Chronic adverse reactions mainly included grade 1–3 trismus, xerostomia, hearing loss, etc. No acute and chronic adverse reactions of grade 4 or higher occurred.

**Discussion**

The recommended treatment for ACCHN is radical surgical resection, combine with postoperative radiotherapy.8

---

![Figure 1](https://example.com/figure1.png)

**Figure 1** Overall survival (OS), distant disease-free survival (DMFS), local-regional recurrence-free survival (LRRFS) for all patients (Kaplan-Meier method).
To date, few studies have reported the clinical outcome and toxicities for ACCHN patients treated by IMRT. In this study, we retrospectively analyzed the outcome of postoperative IMRT for 55 patients with ACCHN, and identified the unfavorable prognostic factors.

Takebayashi et al\(^9\) have reported the 5-year LRRFS, DMFS and OS were 79.3%, 62.6% and 82.2% in 130 patients with ACCHN treated by surgery and radiotherapy. The SEER database\(^4\) showed locally advanced ACCHN 5-year OS was 78.9–93.9%. The 5-year LRRFS, DMFS and OS in this study were 93.9%, 75.3% and 82.5%, respectively, similar to previous reports. Controversially, Ko et al\(^10\) showed that the 5-year OS, DFS and DMFS were 64.5%, 46.2% and 60% in 60 ACCHN patients treated by surgery, with or without adjuvant radiation therapy. However, nearly half the patients in this study received either surgery alone or radiotherapy alone. This may be the reason for the lower OS rate. In our study, results showed that distant metastasis is the main failure manner of ACCHN treatment, the most common metastatic site is lung, and among these patients with lung metastases, none oligometastasis was observed, which is consistent with an international cooperation study.\(^2\)

Surgery plays a crucial role in the treatment of ACCHN. Due to the high invasiveness, especially the neural invasion characteristic of the tumor, the R0 resection is difficult to be reached. Postoperative radiotherapy was an effective complementary treatment for locally advanced ACCHN with a residual microscopic tumor. Our data showed that T stage and clinical stage were independent prognostic factors associated with OS. Previous studies\(^11–14\) have shown that the larger size of tumors and higher T stage were associated with poor prognosis. In univariate analysis of this study, patients with a higher T stage significantly associated with worse OS. Multivariate analysis showed that T staging remain significance for prognosis, comparable with the results in Choi et al study.\(^15\)

### Table 2 Univariate Analysis for Overall Survival (OS), Distant Disease-Free Survival (DMFS) and Local-Regional Recurrence-Free Survival (LRRFS)

|                     | OS (%) | P    | DMFS (%) | P    | LRRFS (%) | P    |
|---------------------|--------|------|----------|------|-----------|------|
| **Gender**          |        |      |          |      |           |      |
| Male                | 79.9   | 0.301| 73.8     | 0.479| 96.6      | 0.629|
| Female              | 87.7   |      | 78.2     | 89.4 |
| **Age, years**      |        |      |          |      |           |      |
| ≤47                 | 82.3   | 0.923| 61.3     | 0.042| 91.7      | 0.869|
| >47                 | 83.0   |      | 88.4     | 96.0 |
| **Primary site**    |        |      |          |      |           |      |
| Large salivary gland| 88.6   | 0.229| 75.9     | 0.958| 92.8      | 0.833|
| Small salivary gland| 75.6   |      | 74.3     | 95.5 |
| **T stages**        |        |      |          |      |           |      |
| 1–2                 | 94.1   | 0.025| 91.5     | 0.041| 100       | 0.049|
| 3–4                 | 73.2   |      | 62.3     | 89.2 |
| **N stages**        |        |      |          |      |           |      |
| 0                   | 82.9   | 0.698| 77.1     | 0.021| 93.5      | 0.598|
| 1–2                 | 75.0   |      | 50.0     | 100.0|
| **AJCC stages**     |        |      |          |      |           |      |
| I–II                | 93.8   | 0.036| 91.1     | 0.021| 100       | 0.065|
| III–IVB             | 74.2   |      | 63.8     | 89.6 |
| **Surgical resection level** | | | | | | |
| R0                  | 93.3   | 0.093| 83.6     | 0.629| 89.7      | 0.621|
| R1& R2              | 76.7   |      | 70.5     | 96.4 |
| **Chemotherapy**    |        |      |          |      |           |      |
| Yes                 | 90.9   | 0.073| 91.6     | 0.010| 88.3      | 0.384|
| No                  | 74.1   |      | 59.9     | 100  |
| **Radiotherapy dose** | | | | | | |
| <60Gy               | 75.6   | 0.509| 69.2     | 0.890| 94.4      | 0.734|
| ≥60Gy               | 86.6   |      | 78.7     | 93.6 |
It has been reported that the primary site is an important factor for local recurrence of ACCHN, nasal sinuses, nasal cavity and submandibular glands were suggested to have higher risk to relapse,\textsuperscript{15,16} controversially, the prognosis of large salivary glands and small salivary glands has no statistical difference.\textsuperscript{17,18} In our study, 30 cases (54.5%) were located in the large salivary gland and 25 cases (45.5%) in the small salivary gland. The LRRFS did not show significant difference between tumor located in the large salivary gland and the small salivary gland. In recent years, clinical studies have shown that postoperative radiotherapy may improve the clinical outcomes of ACCHN patients. A retrospective study\textsuperscript{15} showed that postoperative radiotherapy (>59Gy) significantly improved local control ($p=0.025$) and DFS ($p=0.001$). Based on a study in a cohort of 198 patients treated by surgery and postoperative radiotherapy, Garden et al\textsuperscript{19} suggested that for patients received a R1 resection, the postoperative radiotherapy dose should be at least 60 Gy, while for patients received a R2 resection, the dose should be 66 Gy. In present study, multivariate statistical analysis showed that radiotherapy dose (>60 Gy) was one of the independent factors for better prognosis. Combine evidence above, we suggested for patients have a residual tumor after operation, treated by IMRT with a higher dose (>60 Gy) may improve the prognosis.

At present, there is no effective method for the prevention and treatment of distant metastasis of ACCHN, and there is no accepted standard chemotherapy regimen. Many studies have shown low response rate of chemotherapy.\textsuperscript{18,20,21} Platinum, doxorubicin and cyclophosphamide were commonly used. The combined regimen was considered to have high toxicities. Signal drug regimen chemotherapy was suggested to be used for the reason of lower toxicities.\textsuperscript{22} Chemotherapy may be effective only in cases with rapid progression. Similarly, the effect of immunotherapy for ACCHN was not satisfactory, even though some studies found that some ACCHN patients express cancer-testis antigen (CTAs), in which pan-MPGE and NY-ESO-1 were both positive, these patients were expected to improve survival rates through specific immunotherapy.\textsuperscript{23} In our study, half the patients received adjuvant chemotherapy. Chemotherapy drugs were platinum-based combination regimens. The results

\begin{figure}
\centering
\includegraphics[width=\textwidth]{figure2.png}
\caption{Five-year overall survival (A), distant disease-free survival (B), and local-regional recurrence-free survival (C) by the Kaplan–Meier method in all patients by T stage.}
\end{figure}
Table 3 Multivariate Analysis for Overall Survival (OS), Distant Disease-Free Survival (DMFS) and Local-Regional Recurrence-Free Survival (LRRFS)

|                      | OS P value | HR (95% CI) | DFMS P value | HR (95% CI) | LRRFS P value | HR (95% CI) |
|----------------------|------------|-------------|--------------|-------------|---------------|-------------|
| T stages 3–4         | 0.026      | 0.088       | 0.053        | 0.272       | 0.991         | 0.087       |
| N stages 1–2         | 0.515      | 0.477       | 0.017        | 0.183       | 0.989         | 0.000       |
| AJCC stages III–IVB  | 0.028      | 0.089       | 0.040        | 0.193       | 0.976         | 0.001       |
| Small salivary gland | 0.334      | 0.446       | 0.985        | 0.987       | 0.505         | 0.296       |
| R1&R2                | 0.066      | 0.122       | 0.153        | 0.358       | 0.527         | 2.978       |
| Chemotherapy No      | 0.897      | 0.883       | 0.137        | 0.311       | 0.116         | 2.908       |
| RT dose ≥60Gy        | 0.025      | 6.628       | 0.241        | 2.231       | 0.651         | 2.131       |

Table 4 Acute and Chronic Adverse Reactions

| Chronic Adverse Reactions | Grade 1 (%) | Grade 2 (%) | Grade 3 (%) |
|---------------------------|-------------|-------------|-------------|
| Myelosuppression          | 9 (16.4)    | 15 (27.3)   | 3 (5.5)     |
| Mucositis                 | 16 (29.1)   | 22 (40.0)   | 5 (9.1)     |
| Dermatitis                | 27 (49.1)   | 11 (20.0)   | 1 (1.8)     |
| Hearing loss              | 5 (9.1)     | 3 (5.5)     | 0 (0)       |
| Trismus                   | 6 (10.9)    | 2 (3.6)     | 1 (1.8)     |
| Xerostomia                | 16 (29.1)   | 8 (14.5)    | 1 (1.8)     |

showed that the addition of adjuvant chemotherapy did not induce a better OS, but improved the control of distant metastasis.

In terms of toxicity, 5.5%, 9.1% and 1.8% of patients had myelosuppression, mucositis, dermatitis, respectively, and other side effects also observed during the treatment, no late grade 4 toxicity was observed. All toxicities were tolerable, and patients were successfully complete the postoperative adjuvant radiotherapy. Our data suggested IMRT had great advantages in adjuvant radiotherapy for patients with ACCHN.

In conclusion, this study supported the use of postoperative IMRT for local ACCHN patients. Considering the side effects and local control rate, we highly recommend adjuvant IMRT to be used in ACCHN patients.

Funding

Grant agency of the Science and Technology Department of Sichuan Province (No.20GJHZ0090). These funding supports the present study in the acquisition of data, analysis of data, and manuscript writing.

Disclosure

The authors declared that they have no conflicts of interest to this work.

References

1. Coca-Pelaz A, Rodrigo JP, Bradley PJ, et al. Adenoid cystic carcinoma of the head and neck—an update. Oral Oncol. 2015;51:652–661. doi:10.1016/j.oraloncology.2015.04.005
2. Amit M, Binenbaum Y, Sharma K, et al. Analysis of failure in patients with adenoid cystic carcinoma of the head and neck. An international collaborative study. Head Neck. 2014;36(7):998–1004. doi:10.1002/hed.23405
3. Jang S, Patel PN, Kimple RJ, et al. Clinical outcomes and prognostic factors of adenoid cystic carcinoma of the head and neck. Anticancer Res. 2017;37(6):3045–3052. doi:10.21873/anticancer.11659
4. Li N, Xu L, Zhao H, et al. A comparison of the demographics, clinical features, and survival of patients with adenoid cystic carcinoma of major and minor salivary glands versus less common sites within the surveillance, epidemiology, and end results registry. Cancer. 2012;118(16):3945–3953. doi:10.1002/cncr.26740
5. Suh Y-G, Lee CG, Kim H, et al. Treatment outcomes of intensity-modulated radiotherapy versus 3D conformal radiotherapy for patients with maxillary sinus cancer in the postoperative setting. Head Neck. 2016;38(Suppl 1):E207–E213. doi:10.1002/hed.23971
6. Hao R, Ma D, Takiar V, et al. Orbital carcinomas treated with adjuvant intensity-modulated radiation therapy. Head Neck. 2016;38(Suppl 1):E580–E587. doi:10.1002/hed.24044
7. Gay HA, Dyk P, Deasy JO, et al. Common Terminology Criteria for Adverse Events (CTCAE) v4.0 based hybrid patient and physician questionnaire for Head and Neck (HN) radiotherapy symptom reporting. Int J Radiat Oncol Biol Phys. 2011;81:S673. doi:10.1016/j.ijrobp.2011.06.929
8. Mendenhall WM, Morris CG, Amdur RJ, et al. Radiotherapy alone or combined with surgery for adenoid cystic carcinoma of the head and neck. Head Neck. 2004;26(2):154–162. doi:10.1002/hed.10380
9. Takebayashi S, Shinohara S, Tamaki H, et al. Adenoid cystic carcinoma of the head and neck: a retrospective multicenter study. Acta Otolaryngol. 2018;138:73–79. doi:10.1080/00016489.2017.1371329
10. Ko JJ, Siever JE, Hao D, et al. Adenoid cystic carcinoma of head and neck: clinical predictors of outcome from a Canadian centre. Curr Oncol Toh Ont. 2016;23:26–33. doi:10.3747/co.23.2898
11. Khan AJ, DiGiovanna MP, Ross DA, et al. Adenoid cystic carcinoma: a retrospective clinical review. Int J Cancer. 2001;96:149–158. doi:10.1002/ijc.1013
12. Oplatek A, Ozer E, Agrawal A, et al. Patterns of recurrence and survival of head and neck adenoid cystic carcinoma after definitive resection. Laryngoscope. 2010;120(1):65–70. doi:10.1002/lary.20684
13. Zhang Q, Yang L, Yang A, et al. Clinical study on 88 cases of adenoid cystic carcinoma in nasal cavity and paranasal sinuses. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2009;44(4):311–314.
14. van Weert S, Bloemena E, van der Waal I, et al. Adenoid cystic carcinoma of the head and neck: a single-center analysis of 105 consecutive cases over a 30-year period. Oral Oncol. 2013;49(8):824–829. doi:10.1016/j.oraloncology.2013.05.004
15. Choi Y, Kim S-B, Yoon DH, et al. Clinical characteristics and prognostic factors of adenoid cystic carcinoma of the head and neck. Laryngoscope. 2013;123(6):1430–1438. doi:10.1002/lary.23976
16. Marcinow A, Ozer E, Teknos T, et al. Clinicopathologic predictors of recurrence and overall survival in adenoid cystic carcinoma of the head and neck: a single institutional experience at a tertiary care center. Head Neck. 2014;36(12):1705–1711. doi:10.1002/hed.23523
17. Bjørndal K, Krogdahl A, Therkildsen MH, et al. Salivary adenoid cystic carcinoma in Denmark 1990–2005: outcome and independent prognostic factors including the benefit of radiotherapy. Results of the Danish Head and Neck Cancer Group (DAHANCA). Oral Oncol. 2015;51(12):1138–1142. doi:10.1016/j.oraloncology.2015.10.002
18. Meyers M, Granger B, Herman P, et al. Head and neck adenoid cystic carcinoma: a prospective multicenter REFCOR study of 95 cases. Eur Ann Otorhinolaryngol Head Neck Dis. 2016;133:13–17. doi:10.1016/j.anorl.2015.09.009
19. Garden AS, Weber RS, Morrison WH, et al. The influence of positive margins and nerve invasion in adenoid cystic carcinoma of the head and neck treated with surgery and radiation. Int J Radiat Oncol Biol Phys. 1995;32(3):619–626. doi:10.1016/0360-3016(95)00122-F
20. Dillon PM, Chakraborty S, Moskaluk CA, et al. Adenoid cystic carcinoma: a review of recent advances, molecular targets, and clinical trials. Head Neck. 2016;38(4):620–627. doi:10.1002/hed.23925
21. Subramaniam T, Lennon P, O’Neill JP. Ongoing challenges in the treatment of adenoid cystic carcinoma of the head and neck. Ir J Med Sci. 2015;184(3):583–590. doi:10.1007/s11845-015-1298-1
22. Papaspyrou G, Hoch S, Rinaldo A, et al. Chemotherapy and targeted therapy in adenoid cystic carcinoma of the head and neck: a review. Head Neck. 2011;33:905–911. doi:10.1002/hed.21458
23. Veit JA, Heine D, Thierauf J, et al. Expression and clinical significance of MAGE and NY-ESO-1 cancer-testis antigens in adenoid cystic carcinoma of the head and neck. Head Neck. 2016;38:1008–1016. doi:10.1002/hed.24403